Literatuur
- Hershman, DL et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol 2016; 2:453
- Attard, G. et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The Lancet 2022; 399:447-460
- Kerkmeijer, LGW et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III rrial. J Clin Oncol 2021 Mar 1; 39(7):787-796
- Groen, VH et al. Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer. Eur Urol 2022; 82:252-257
- Gillessen, S et al. Management of patients with advanced prostate cancer - metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC). Eur J Cancer 2023; 185:178-215
- Wang, L. et al. Comparison of systemic treatments for metastatic castration-sensitive prostate cancer. JAMA Oncol 2021; 7:412
- Stenzl A et al. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate 2022; 82:1237–1247
- Sydes MR et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology 2018; 29:1235-1248
- Smith, MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. New England Journal of Medicine 2022; 386:1132-1142
- Fizazi, K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2*2 factorial design. Lancet 2022 Apr 30; 399(10336):1695-1707
- Kyriakopoulos, CE et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. Journal of Clinical Oncology 2018 Apr 10; 36(11):1080-1087
- Clarke, NW et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology 2019; 30:1992-2003
- Fizazi, K et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine 2017; 377:352-360
- Chi, KN et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. Journal of Clinical Oncology 2021; volume 39 number 20
- Armstrong, AJ et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology 2022; 40:1616-1622
- Armstrong, AJ et al. Arches: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology 2019; 37:2974-2986
- Fizazi, K et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine 2019; 380:1235-1246
- Sternberg, CN et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine 2020; 382:2197-2206
- Berthold, DR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242–5
- Fizazi, K et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983-992
- Ryan, CJ et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16:152-60
- Scher, HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 2012; 367:1187–97
- Beer, TM et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine 2014 Jul 31; 371(5)424-33
- De Bono, J et al. Olaparib for metastatic castration-resistant prostate cancer. New England Journal of Medicine 2020; 382:2091-2102
- Hussain, M et al. Survival with olaparib in metastatic castration-resistant prostate cancer. New England Journal of Medicine 2020; 383:2345-2357
- Parker, C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213-223
- Cabazitaxel at 20 mg/m2 Compared to 25 mg/m2 With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA). Vermelding op website Clinicaltrials.gov
- De Bono, JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154
- Corn, PG et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 2019; 20:1432-1443
- Sartor, O et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. New England Journal of Medicine 2021; 385:1091-1103
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over prostaatcarcinoom.
Richtlijnen
Ga naar de richtlijn Prostaatcarcinoom in de FMS richtlijnendatabase.
Ga naar de richtlijn Prostaatcarcinoom van VKGN - StOET.